Cambridge gene therapy firm Alnylam is changing alliances, cutting research ties with longtime partner Sanofi and partnering with Regeneron on new eye and central nervous system treatments.
Alnylam (Nasdaq: ALNY) has entered into an exclusive partnership with New York-based Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to develop treatments that silence harmful RNA that contribute to various diseases.
In addition to a $400 million upfront payment, Regeneron is investing another $400 million in…
